The 2025 American Academy of Dermatology (AAD) conference was held in Orlando, Florida, from March 7–11, 2025. This post-conference report highlights key developments across atopic dermatitis, alopecia areata, and psoriasis. Promising data were presented for several novel therapies, including the anti-OX40 antibody rocatinlimab for atopic dermatitis, the anti-IL-7R antibody bempikibart for severe alopecia areata, and the oral IL-23R inhibitor icotrokinra for psoriasis.

Indications covered:

Atopic dermatitis

Alopecia areata

Psoriasis

Prurigo nodularis

Bullous pemphigoid